New analysis signifies that utilizing imaging to detect silent atherosclerosis from early maturity might present a chance to enhance major prevention methods and scale back the worldwide burden of atherosclerotic heart problems (CVD).
The REACT research, funded by Novo Nordisk Basis and offered on the 2026 European Society of Cardiology (ESC) congress, going down 28-31 August in Munich, Germany, used imaging to measure silent atherosclerosis in 16,808 adults with out identified CVD aged 18 to 70 years previous in a cross-sectional research.
Researchers concerned in REACT used three-dimensional vascular ultrasound to evaluate atherosclerosis within the carotid and femoral arteries, and CT angiography for the coronary arteries.
Silent atherosclerosis, referring to the gradual, asymptomatic buildup of fatty plaque within the arteries that may result in stroke and coronary heart assault, was current in 57.1% of contributors. The analysis discovered that the situation was already current in roughly 1 in 13 contributors aged 18–29 years and 9 out of 10 contributors aged 60–70 years, with prevalence growing with age in an S-shaped curve.
Atherosclerosis prevalence elevated earlier in males, with girls displaying a later and particularly pronounced mid-life will increase. In the meantime, rising age was related to growth of atherosclerosis and an exponential enhance in age-related atherosclerotic plaque quantity.
Following presentation of the REACT research’s outcomes at ESC 2026, the info has been revealed within the New England Journal of Drugs.
Professor Henning Bundgaard from Denmark’s Rigshospitalet – Copenhagen College Hospital,, who co-led the REACT research, commented: “These knowledge from a number of areas assist the idea of silent atherosclerosis as a systemic, progressive illness course of with males exhibiting an roughly 5-to-10-year earlier atherosclerotic trajectory than girls.”
The researchers additionally examined the extent to which standard cardiovascular danger evaluation classifies contributors with silent atherosclerosis as excessive danger. They discovered that the SCORE2 danger instrument categorized solely a small minority of contributors with silent atherosclerosis on this group, with a marked lack amongst youthful contributors.
Bundgaard continued: “Figuring out and treating silent atherosclerosis as early as potential might assist scale back the worldwide burden of CVD. Our findings assist additional potential research to analyze whether or not imaging-guided therapy of these with early proof of illness — detected utilizing a handheld ultrasound scanner – can enhance present requirements. If profitable, this might assist a precision drugs strategy to atherosclerotic heart problems.”
Primarily based on the offered findings, a significant randomised trial is deliberate as a part of the second section of the REACT initiative.
CVDs are the main explanation for loss of life globally. An estimated 19.8 million individuals died from CVDs in 2022, representing roughly 32% of all international deaths, as per the World Well being Group (WHO).
“ESC 2026: Figuring out ‘silent’ atherosclerosis might assist scale back international CVD burden” was initially created and revealed by Medical Device Network, a GlobalData owned model.
